As per global strategy for dengue prevention and control, 2012-2020, WHO objectives include reduction in dengue mortality by at least 50% by 2020 and reduction in dengue morbidity by at [...]
To date, no rapid diagnostic tests have been validated and licensed for the indication of screening for seropositivity. Dengue IgG ELISA could potentially be used for screening (enzyme-linked immunosorbent assay). [...]
SAGE recommended preferred approach to dengue vaccine is prevaccination screening with only confirmed dengue-seropositive persons receiving vaccination. The alternate approach using population seroprevalence, involves mass vaccination in identified high seroprevalence [...]
SAGE recommends that countries should consider introduction of CYDTDV only in geographic settings with high endemicity. When seroprevalence is below 50%, the vaccine is not recommended.
The WHO Strategic Advisory Group of Experts on immunization (SAGE) working group has acknowledged the public health role of the CYD-TDV vaccine and the strong protective benefit in seropositive individuals [...]
Rigorous implementation of vector control measures is important. Sterile Insect Techniques, Wolbachia strategy and genetically modified mosquito are newer methods of vector control.
Coordination of regional initiatives, sustained prioritization and resourcing, and continuous advocacy with strong supportive evidence base is necessary to develop an integrated surveillance system across Asia.
Digital surveillance involving real-time, customizable, web based information systems, allow monitoring of cases, alert outbreaks, identify resources and operational costs, determine efficacy of vector control strategies. Join us at the [...]
Robust disease surveillance system is important to understand the epidemiological and clinical profiles of dengue and is a key to enhance epidemic preparedness and outbreak response capacity.